Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis-Reference-Cited by-同舟云学术

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis

Published:2022-02 Issue: Volume:162 Page:22-33
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Goldinger Simone M.,Buder-Bakhaya Kristina,Lo Serigne N.^ORCID,Forschner Andrea^ORCID,McKean Meredith^ORCID,Zimmer Lisa^ORCID,Khoo Chloe,Dummer Reinhard,Eroglu Zeynep,Buchbinder Elizabeth I.,Ascierto Paolo A.^ORCID,Gutzmer Ralf,Rozeman Elisa A.,Hoeller Christoph^ORCID,Johnson Douglas B.,Gesierich Anja,Kölblinger Peter^ORCID,Bennannoune Naima,Cohen Justine V.^ORCID,Kähler Katharina C.^ORCID,Wilson Melissa A.,Cebon Jonathan,Atkinson Victoria,Smith Jessica L.^ORCID,Michielin Olivier,Long Georgina V.^ORCID,Hassel Jessica C.^ORCID,Weide Benjamin,Haydu Lauren E.^ORCID,Schadendorf Dirk^ORCID,McArthur Grant,Ott Patrick A.,Blank Christian,Robert Caroline,Sullivan Ryan,Hauschild Axel^ORCID,Carlino Matteo S.,Garbe Claus^ORCID,Davies Michael A.,Menzies Alexander M.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference34 articles.

1. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma;Larkin;N Engl J Med,2019

2. Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy;Saab;Cancer,2019

3. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma;Zimmer;Eur J Cancer,2017

4. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study;Pires da Silva;Lancet Oncol,2021

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Imaging of Melanoma VEGF-expressing Tumors through [^99mTc]Tc-HYNIC-Fab(Bevacizumab);Anti-Cancer Agents in Medicinal Chemistry;2024-11

2. Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance;Annual Review of Immunology;2024-06-28

3. Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study;JAAD International;2024-06

4. Systemic Treatment of Melanoma;Rook's Textbook of Dermatology;2024-03-19

5. Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care;The Cancer Journal;2024-03